One of the most effective yet commonly used chemotherapy agents in cancer patients is known as doxorubicin (DOX), a type of anthracycline. However, this agent is known to have toxic effects on the cardiovascular system and is linked to multiple cardiovascular diseases. Various studies have shown that cancer survivors who had received DOX treatment had developed congestive heart failure (CHF); those with histories of pre-existing cardiovascular diseases were also at greater risk. At the Zordoky Lab, a lab from the Experimental and Clinical Pharmacology Department at the University of Minnesota, I conducted research on growth differentiation factor 15 (GDF-15), which is a member of the transforming growth factor-𝛽 superfamily. Existing literature has shown that this cytokine could potentially be a cardioprotective agent against DOX-induced toxicity, as it is secreted from tissues when patients undergo chemotherapy. To study this, we looked at three models: clinical, in vivo, and in-vitro to establish whether GDF-15 is protective or not. Although the findings were inconclusive,  more research is warranted as there is a translational significance in this work. Understanding the effects that GDF-15 may have against DOX will help us establish other attributes, such as its mechanism of action. Advancing these findings in future clinical studies will determine whether or not it is beneficial or detrimental for patients.